PDT Partners’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-34,271
| Closed | -$4.39M | – | 595 |
|
|
2025
Q2 | $4.39M | Buy |
34,271
+28,173
| +462% | +$2.93M | 0.25% | 139 |
|
|
2025
Q1 | $540K | Buy |
6,098
+3,000
| +97% | +$293K | 0.04% | 513 |
|
|
2024
Q4 | $270K | Buy |
+3,098
| New | +$284K | 0.02% | 602 |
|
|
2024
Q2 | – | Sell |
-15,129
| Closed | -$1.44M | – | 668 |
|
|
2024
Q1 | $1.44M | Sell |
15,129
-4,398
| -23% | -$377K | 0.14% | 257 |
|
|
2023
Q4 | $1.8M | Sell |
19,527
-3,641
| -16% | -$236K | 0.2% | 171 |
|
|
2023
Q3 | $1.16M | Sell |
23,168
-26
| -0.1% | -$1.39K | 0.15% | 248 |
|
|
2023
Q2 | $1.47M | Buy |
23,194
+9
| +0% | +$489 | 0.2% | 176 |
|
|
2023
Q1 | $1.04M | Sell |
23,185
-5,933
| -20% | -$267K | 0.14% | 250 |
|
|
2022
Q4 | $1.28M | Buy |
29,118
+11,170
| +62% | +$536K | 0.21% | 176 |
|
|
2022
Q3 | $1.18M | Buy |
+17,948
| New | +$1.15M | 0.18% | 173 |
|
|
2022
Q2 | – | Sell |
-3,874
| Closed | -$247K | – | 969 |
|
|
2022
Q1 | $247K | Buy |
+3,874
| New | +$278K | 0.02% | 773 |
|
|
2021
Q2 | – | Sell |
-46,000
| Closed | -$4.47M | – | 807 |
|
|
2021
Q1 | $4.47M | Sell |
46,000
-8,918
| -16% | -$890K | 0.32% | 90 |
|
|
2020
Q4 | $6.16M | Sell |
54,918
-9,582
| -15% | -$1.01M | 0.42% | 51 |
|
|
2020
Q3 | $5.98M | Sell |
64,500
-4,531
| -7% | -$349K | 0.39% | 98 |
|
|
2020
Q2 | $5.38M | Sell |
69,031
-26,596
| -28% | -$1.8M | 0.37% | 113 |
|
|
2020
Q1 | $5.59M | Buy |
95,627
+34,627
| +57% | +$2.23M | 0.44% | 85 |
|
|
2019
Q4 | $4.89M | Buy |
61,000
+3,300
| +6% | +$247K | 0.3% | 115 |
|
|
2019
Q3 | $4.24M | Buy |
57,700
+40
| +0.1% | +$3.46K | 0.25% | 128 |
|
|
2019
Q2 | $5.44M | Buy |
+57,660
| New | +$4.76M | 0.32% | 106 |
|
Other funds holding BPMC
IA
HNB
PDT Partners's BPMC Position: Q3 2025 in Review
PDT Partners sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 34,271 shares — an estimated $4.39M sold.
PDT Partners first reported a position in BPMC in Q2 2019 and held it in 19 quarters. The position peaked at $6.16M in Q4 2020. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- PDT Partners reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- PDT Partners sold 34,271 Blueprint Medicines shares in Q3 2025, an estimated $4.39M.
- PDT Partners first reported a position in Blueprint Medicines in Q2 2019 and held it in 19 quarters.
- PDT Partners's Blueprint Medicines position peaked at $6.16M in Q4 2020.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on PDT Partners's 13F filing for Q3 2025, filed 17 Nov 2025.